Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming

por Atanackovic, Djordje, Altorki, Nasser K., Cao, Yanran, Ritter, Erika, Ferrara, Cathy A., Ritter, Gerd, Hoffman, Eric W., Bokemeyer, Carsten, Old, Lloyd J., Gnjatic, Sacha
Publicado em 2008

Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer

por Odunsi, Kunle, Qian, Feng, Matsuzaki, Junko, Mhawech-Fauceglia, Paulette, Andrews, Christopher, Hoffman, Eric W., Pan, Linda, Ritter, Gerd, Villella, Jeannine, Thomas, Bridget, Rodabaugh, Kerry, Lele, Shashikant, Shrikant, Protul, Old, Lloyd J., Gnjatic, Sacha
Publicado em 2007

Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma

por Ott, Patrick A., Carvajal, Richard D., Pandit-Taskar, Neeta, Jungbluth, Achim A., Hoffman, Eric W., Wu, Bor-Wen, Bomalaski, John S., Venhaus, Ralph, Pan, Linda, Old, Lloyd J., Pavlick, Anna C., Wolchok, Jedd D.
Publicado em 2012

A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinoma

por Davis, Ian D., Liu, Zhanqi, Saunders, Wayne, Lee, Fook-Thean, Spirkoska, Violeta, Hopkins, Wendie, Smyth, Fiona E., Chong, Geoffrey, Papenfuss, Anthony T., Chappell, Bridget, Poon, Aurora, Saunder, Timothy H., Hoffman, Eric W., Old, Lloyd J., Scott, Andrew M.
Publicado em 2007

A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma

por Davis, Ian D., Wiseman, Gregory A., Lee, Fook-Thean, Gansen, Denise N., Hopkins, Wendie, Papenfuss, Anthony T., Liu, Zhanqi, Moynihan, Timothy J., Croghan, Gary A., Adjei, Alex A., Hoffman, Eric W., Ingle, James N., Old, Lloyd J., Scott, Andrew M.
Publicado em 2007

Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using Toll-like receptor 7 agonist imiquimod as vaccine adjuvant

por Adams, Sylvia, O'Neill, David W., Nonaka, Daisuke, Hardin, Elizabeth, Chiriboga, Luis, Siu, Kimberly, Cruz, Crystal M., Angiulli, Angelica, Angiulli, Francesca, Ritter, Erika, Holman, Rose Marie, Shapiro, Richard L., Berman, Russell S., Berner, Natalie, Shao, Yongzhao, Manches, Olivier, Pan, Linda, Venhaus, Ralph R., Hoffman, Eric W., Jungbluth, Achim, Gnjatic, Sacha, Old, Lloyd, Pavlick, Anna C., Bhardwaj, Nina
Publicado em 2008

A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors

por Scott, Andrew M., Lee, Fook-Thean, Tebbutt, Niall, Herbertson, Rebecca, Gill, Sanjeev S., Liu, Zhanqi, Skrinos, Effie, Murone, Carmel, Saunder, Timothy H., Chappell, Bridget, Papenfuss, Anthony T., Poon, Aurora M. T., Hopkins, Wendie, Smyth, Fiona E., MacGregor, Duncan, Cher, Lawrence M., Jungbluth, Achim A., Ritter, Gerd, Brechbiel, Martin W., Murphy, Roger, Burgess, Antony W., Hoffman, Eric W., Johns, Terrance G., Old, Lloyd J.
Publicado em 2007

Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans

por Davis, Ian D., Chen, Weisan, Jackson, Heather, Parente, Phillip, Shackleton, Mark, Hopkins, Wendie, Chen, Qiyuan, Dimopoulos, Nektaria, Luke, Tina, Murphy, Roger, Scott, Andrew M., Maraskovsky, Eugene, McArthur, Grant, MacGregor, Duncan, Sturrock, Sue, Tai, Tsin Yee, Green, Simon, Cuthbertson, Andrew, Maher, Darryl, Miloradovic, Lena, Mitchell, Susan V., Ritter, Gerd, Jungbluth, Achim A., Chen, Yao-Tseng, Gnjatic, Sacha, Hoffman, Eric W., Old, Lloyd J., Cebon, Jonathan S.
Publicado em 2004